Study of BHV-1300 in Graves' Disease
Key facts
- Where
- Canton, Columbus, Dallas, Greenville, Houston, Memphis, Miami, Shavano Park, and South Gate, United StatesSee the 10 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06980649, who can take part
Where in United States
- Canton, OhioHospital not named in the registryContact: Chief Medical OfficerTaking people
- Columbus, GeorgiaHospital not named in the registryContact: Chief Medical OfficerTaking people
- Dallas, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
- Greenville, North CarolinaHospital not named in the registryContact: Chief Medical OfficerTaking people
- Houston, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
- Houston, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
- Memphis, TennesseeHospital not named in the registryContact: Chief Medical OfficerTaking people
- Miami, FloridaHospital not named in the registryContact: Chief Medical OfficerTaking people
- Shavano Park, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
- South Gate, CaliforniaHospital not named in the registryContact: Chief Medical OfficerTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Biohaven Therapeutics Ltd.
- Trial code
- NCT06980649
- Record updated
- 31 July 2026
- Original description
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.Read full original descriptionShow less
An Open-Label Biomarker Study of BHV-1300 in Graves' Disease
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
Inclusion: Participants must have serologically confirmed Graves' Disease.
Exclusion: History of treatment with radioactive iodine or thyroid surgery; History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit.